Ahmed Abdelshafy Tabl
Banhā, Benha, 13511, Egypt
NCT Number: NCT05114928
Keratoconus is a progressive corneal disease characterized by asymmetric corneal thinning and structural changes in corneal collagen which leads to decrease in visual acuity due to myopic shift, irregular astigmatism or corneal scarring. Early detection of the disease in children aids in halting the progression and improve their quality of life. There is no consensus regarding the progression criteria of the disease, we aimed to assess the changes in corneal asphericity in children after corneal collagen crosslinking and investigate any possible correlation with progression criteria widely used.
Looking for future studies?
Notify Me6 year–16 year
All sexes
Observational
Banhā, Benha, 13511, Egypt
The Keratoconus progression is defined as increasing by 1.0 diopter (D) or more in the maximum keratometry (Kmax), progressive deterioration in Minimal Corneal Thickness is also associated with KC progression, other methods have been investigated to confirm KC progression such as changes in manifest refraction, unaided visual acuity (UAVA), BCVA, posterior keratometric data and higher order aberrations (HOA) which are altered in KC and can aid to confirm disease progression. Q-value (a coefficient of corneal asphericity) reflects the shape of the cornea, its refractive power, and spherical aberration. The mean Q-value in normal cornea is -0.26 ± 0.18, the severity of KC and the Q-value are inversely related.
Mean Q-value in KC at 8mm zone is -0.84 and -1.10 for anterior and posterior corneal surfaces, respectively. Until now, no precise criteria of KC progression especially in cases had undergone previous trans-epithelial corneal collagen cross-linking (TE-CXL) to halt the progression of the disease. In the present study we aimed to analyze the correlation between the changes in Q-value and progression of the KC in children had undergone bilateral TE-CXL.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Children that were diagnosed as bilateral progressive KC (stage I-III, according to amsler classification, Kmax change >1D between 2 scanning with at least 2 months apart), and their age were less than 16 years old at time of TE-CXL, topographic parameters were Kmax 47-60D and MCT more than 400μm.
Exclusion criteria
Eyes with central corneal scarring, amblyopic eyes, and other corneal pathologies that may alter Pentacam scanning.
Bilateral Transepithelial Corneal Collagen Cross-linking was done for all subjects using power of 9mW/cm2 at 55mm from the cornea for 10 minutes, with a total energy of 5.4j/cm2 using the (CCL VARIO, PESCHKE Trade GmbH, Huenenberg Switzerland), in the period between January 2016 to August 2016.
Other names: TE-CXL
Pentacam (OCULUS Optikgeräte GmbH, Wetzlar, Germany) was done for all subjects at baseline and annually after TE-CXL till 5 years of follow-up.
Other names: Pentacam
Time frame: Baseline and annually after TE-CXL till 5 years of follow-up
Evaluate the changes in Q-value after Trans-epithelial corneal collagen cross-linking (TE-CXL) using pentacam.
Time frame: Baseline and annually after TE-CXL till 5 years of follow-up
Correlation between the changes in Q-value in different corneal zones and maximum keratometry and minimal corneal thickness in both groups over 5 years of follow-up.
Time frame: Baseline and annually after TE-CXL till 5 years of follow-up
The possibility of using the Q-value parameters as a predictive values to confirm keratoconus progression in children.
Benha University
Other
Correlation Between Changes in Corneal Asphericity and Progression of Keratoconus in Children
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03990506
Corneal Biomechanics, Corneal Crosslinking
Umeå, Sweden
View Trial DetailsNCT04475900
Astigmatism, Corneal Astigmatism
Dresden, Saxony, Germany
View Trial DetailsNCT04251143
Astigmatism, Corneal Astigmatism
Dresden, Saxony, Germany
View Trial DetailsNCT01843101
Corneal Diseases, Corneal Neovascularisation
Vienna, Austria
View Trial Details